viewG Medical Innovations Holdings Ltd

G Medical Innovations board member buys $107,791 worth of out-of-the-money options

The options have a 30-cent strike price and expire 1 May 2020.

nasdaq sign
The company recently gained SEC approval for a NASDAQ listing

G Medical Innovations Holdings Ltd (ASX:GMV) non-executive director Brendan de Kauwe has purchased 2.5 million unlisted options for $107,791.

The options have a 30-cent exercise price, well above the last traded price of 19 cents and expire 1 May 2020.

For these options to have value, the share price must be above 30 cents before this date.

READ: G Medical Innovations releases prospectus for NASDAQ listing after obtaining SEC approval

Earlier this week, G Medical released its prospectus detailing a dual-listing on the NASDAQ Capital Market.

The company proposes to raise a minimum of US$17 million through the offer of American Depositary Shares (ADS).

The executives of the company will commence a US investor roadshow on 3 June 2019, after the mandatory exposure period concludes.

Quick facts: G Medical Innovations Holdings Ltd

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of G Medical Innovations Holdings Ltd named herein, including the promotion by the Company of G Medical Innovations Holdings Ltd in any Content on...


Australian e-health company G Medical Innovations eyes Nasdaq listing

G Medical Innovations Holdings Ltd (ASX:GMV) CEO Yacov Geva sits down with Proactive Investors' Christine Corrado in New York to update investors on the mobile and e-health company's move to list on the Nasdaq. Geva says the company, which specializes in software and devices that aim to...

on 16/10/18

2 min read